Compare VALU & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | CAPR |
|---|---|---|
| Founded | 1931 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.4M | 324.6M |
| IPO Year | N/A | N/A |
| Metric | VALU | CAPR |
|---|---|---|
| Price | $37.48 | $26.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.14 |
| AVG Volume (30 Days) | 3.1K | ★ 5.7M |
| Earning Date | 12-15-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 6.17 | N/A |
| EPS | ★ 2.26 | N/A |
| Revenue | ★ $34,801,000.00 | $11,130,509.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7,736.03 |
| P/E Ratio | $16.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $32.94 | $4.30 |
| 52 Week High | $55.01 | $40.37 |
| Indicator | VALU | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 79.98 |
| Support Level | $36.50 | $4.30 |
| Resistance Level | $38.60 | $40.37 |
| Average True Range (ATR) | 0.74 | 2.60 |
| MACD | 0.17 | 2.56 |
| Stochastic Oscillator | 52.29 | 62.78 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.